Trial Profile

Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BGB A445 (Primary) ; Tislelizumab (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors BeiGene

22 May 2025 According to the BeiGene media release, final analysis from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 -June 3, 2025.
06 Feb 2025 Status changed from active, no longer recruiting to completed.
13 Aug 2024 Planned End Date changed from 16 Sep 2024 to 29 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com